Checkmate Pharmaceuticals — Investor Presentation (October 2021)
24 slides from Checkmate Pharmaceuticals's investor presentation, Oct 4, 2021
Slide 1: Heating Up Cancer Immunotherapy
Heating Up Cancer Immunotherapy October 2021 Exhibit 99.1
Slide 2: Forward Looking Statement
Forward Looking Statement Certain statements in this presentation (“Presentation”) that are not statements of historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such forward-looking statements include tho
Slide 3: Investment Highlights
Investment Highlights Vidutolimod (CMP-001) is an innate immune modulator with the potential to become a backbone of I/O combinations 28% ORR in PD-1 refractory melanoma1; similar magnitude of regression in injected and non-injected lesions 67% pathologic response in PD-1 naïve neoadjuvant melanoma
Slide 4: Vidutolimod (CMP-001) can activate a T cell response
Vidutolimod (CMP-001) can activate a T cell response 30 nm Qbeta Potent Type A CpG DNA payload (G10) Mimics viral, retroviral DNAs Synthesized on native phosphodiester backbone Most potent inducer of type I IFN known, drives T cell immune response G10 CpG-A Oligonucleotide Immune stimulating virus-l
Slide 5: Vidutolimod can stimulate a powerful systemic T cell response against a tumor
Vidutolimod can stimulate a powerful systemic T cell response against a tumor 1 Antibody-bound vidutolimod is taken up by pDC and activates TLR9 2 Activated pDC recruit and stimulate other immune cells; Type I IFN enhances T cell activation directly and indirectly, e.g., CXCL10 primary PD marker for
Slide 6: CPG-A Induces the Highest Type I IFN, and Lowest Inflammatory Cytokine
CPG-A Induces the Highest Type I IFN, and Lowest Inflammatory Cytokine 1OOR = out of range IFN-α IL-6 TNF IL-10 IL-1β Luminex cytokine/chemokine multiplex of supernatants from normal human PBMC, performed using optimal conditions and concentrations for each agent at the University of Iowa Cancer Cen
Slide 7: Systemic Effect via Local Activation
Systemic Effect via Local Activation Local injection into tumors to trigger an antigen-specific anti-tumor T cell response Evidence of systemic effect in non-injected lesions Requires a single lesion accessible for injection Cutaneous or subcutaneous lesions, or palpable lymph nodes Injections perfo
Slide 8: Maturing and Expanding Set of Target Indications
Maturing and Expanding Set of Target Indications Note: Refractory Melanoma represents Anti PD-1 Refractory Melanoma, 1L Melanoma represents Anti PD-1 Naïve, Metastatic or Unresectable Melanoma, Neoadjuvant Melanoma represents Anti PD-1 Naïve, Neoadjuvant Melanoma, and First Line HNSCC represents Ant
Slide 9: Large and Growing Market Opportunity in Melanoma
Large and Growing Market Opportunity in Melanoma US Market1 High unmet need in melanoma with continued expected growth Standard of care Anti PD-1 (pembrolizumab or nivolumab) Opportunity Significant room for improvement vs. single agent anti PD-1 in front-line melanoma Single agent front-line anti P
Slide 10: Phase 1b Study in PD-1 Refractory Melanoma
Phase 1b Study in PD-1 Refractory Melanoma Prior cancer therapies Any PD-1 100% Any ipilimumab 47% Prior PD-1 best response CR (complete response) 4% PR (partial response) 13% SD (stable disease) 31% PD (progressive disease) 43% Prior PD-1 last response SD (stable disease) 3% PD (progressive disease
Slide 11: Clinically Meaningful Response in Refractory Patient Population
Clinically Meaningful Response in Refractory Patient Population 1RECISTv1.1, Data 17 August 2021 2RECISTv1.1 plus post-progression responses, Data cutoff August 17, 2021 3Response to treatment beyond progression with anti-PD-1. Ahmed, F.S., et al., Eur Radiol, 2020; 6/78 iPR/iCR after intial PD by R
Slide 12: Robust Depth of Response
Robust Depth of Response PD (progressive disease) . SD (stable disease) PR (partial response) CR (complete response) Post-PD response Change From Baseline of Target Lesions ( %) 120 100 80 60 40 20 -20 -40 -60 -80 -100 RECIST Partial Response: -30% Note: N=98 subjects who received formulation A, inc
Slide 13: Highly Durable Responses
Highly Durable Responses Note: N=37, RECIST v1.1 responders and Post-progression responders; Data cutoff September 30, 2020 Median duration of response 19.9 months RECIST v1.1 Disease Status CR PR SD PD Vidutolimod + Pembrolizumab No Vidutolimod treatment 6 month 1 year 2 years 3 years 4 years 0 6 1
Slide 14: Systemic (Abscopal) Effect Observed in Distant Visceral Lesions
Systemic (Abscopal) Effect Observed in Distant Visceral Lesions 48-year-old WF with metastatic bilateral lung disease Progressed after prior therapies of ipilimumab (adjuvant), interferon (adjuvant), pembrolizumab, IL-2, aflibercept Injection site: right inguinal lymph node (groin) Non-injected Targ
Slide 15: Systemic Effect Observed in Non-Injected Lesions
Systemic Effect Observed in Non-Injected Lesions Injected lesions, mean regression 71% Non-Injected lesions, mean regression 62% Responders with Injected Target Lesions Only (n=15) Responders with Non-Injected Target Lesions (n=22) RECIST Partial Response: -30% Note: N=37, RECIST v1.1 responders and
Slide 16: Vidutolimod Monotherapy Activity Supportive of Further Development In Combination
Vidutolimod Monotherapy Activity Supportive of Further Development In Combination Vidutolimod has shown monotherapy activity The median DOR (5.6 months; RECIST) is substantially shorter than that of combination therapy Supportive of further development in combination Data cutoff August 17, 2021 22.5
Slide 17: Treatment-Related Adverse Events Were Generally Manageable
Treatment-Related Adverse Events Were Generally Manageable No Grade 5 TRAE reported; Data cutoff: August 17, 2021 Vidutolimod + Pembrolizumab (n=159) Grade 3 or 4 Treatment-Related Adverse Events 37.1% (59/159) of subjects Most common (≥ 3 subjects): hypotension (n=11, 7%); hypertension (n=8, 5%); c
Slide 18: Neoadjuvant Study Design
Neoadjuvant Study Design1 1Davar et al, SITC 2020; Data cutoff: October 1, 2020 2Tetzlaff Ann Oncol 2018, 29 (8): 1861-1868. Pathologic Response2 Residual Viable Tumor MPR Complete Response (pCR) 0% Major Response (pMR) ≤10% Partial Response (pPR) >10% & <50% Non-Response (pNR) >50% Primary endpoint
Slide 19: Compelling Pathologic Response and Year Relapse Free Survival
Compelling Pathologic Response and 1 Year Relapse Free Survival 1Davar Hillman Cancer Center Study 17-169, ClinicalTrials.gov Identifier: NCT03618641 September 16, 2021 2Tetzlaff Ann Oncol 2018, 29 (8): 1861-1868. [% Residual Viable Tumor: pCR = 0; pMR <10%; pPR 10 - 50%; pNR >50%] 3MPR = major path
Slide 20: Treatment-Related Adverse Events Were Generally Manageable
Treatment-Related Adverse Events Were Generally Manageable No delays or surgical complications related to therapy Davar et al, SITC 2020; Data cutoff: October 1, 2020; Data is based on preliminary analysis. Vidutolimod/Nivolumab (N=31) AE Term, N (%) Grade 1 (n/%) Grade 2 (n/%) Grade 3 (n/%) Grade 4
Slide 21: Next Steps for Vidutolimod Development
Next Steps for Vidutolimod Development 2021 2022 2023 2024 Melanoma Refractory Melanoma* Vidutolimod + nivo PD-1 refractory, n=100 Front Line* Vidutolimod + nivo vs nivo CPI-naïve , n=140 Neoadjuvant Melanoma Vidutolimod + nivo CPI-naïve, n=30 HNSCC Vidutolimod + pembro CPI-naïve , n=43 Non-melanoma
Slide 22: Rich Flow of New Data in 2022
Rich Flow of New Data in 2022 Head and neck cancer potential interim data readouts beginning 1H 2022 Head and neck cancer anticipated full ORR readout 2H 2022 Cutaneous squamous cell and Merkel cell carcinomas potential interim data readouts in 2H 2022 Melanoma registration program topline data read
Slide 23: Experienced Management Team / Corporate Highlights
Experienced Management Team Headquarters in Cambridge, MA Completed IPO in August 2020 As of June 30, 2021 Cash and Cash equivalents of $95.6M Common stock shares outstanding 21.6 million No debt Cash runway through end of 2022 Corporate Highlights
Slide 24: Investment Highlights
Investment Highlights Vidutolimod (CMP-001) is an innate immune modulator with the potential to become a backbone of I/O combinations 28% ORR in PD-1 refractory melanoma1; similar magnitude of regression in injected and non-injected lesions 67% pathologic response in PD-1 naïve neoadjuvant melanoma
Checkmate Pharmaceuticals — Investor Presentation (October 2021) on 6ix